Adrenaline Auto-Injector Prescribing in Primary Care in England: An Analysis of Non-Standard Dosing.

ABSTRACT:

Introduction

The recommended first-line treatment for anaphylaxis in the community is intramuscular injection of adrenaline. The treatment is a standardised dose of either a 150 μg or a 300 μg adrenaline auto-injector (AAI) device depending upon the patient's weight. Currently, no standardised mechanisms exist to transition patients onto the higher 300 μg dose when they reach 25-30 kg (depending upon the manufacturer).

Methods

We undertook analysis of NHS prescriptions data dispensed in the community in England to identify rates of non-standard AAI dose prescribing. Non-standard prescribing is defined as patients who are likely to have exceeded the 25-30 kg threshold but still received a 150 μg dose. Data were limited to the most recent AAI prescription for an individual pat

SUBMITTER: Michaelis LJ 

PROVIDER: S-EPMC12774575 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature